1. El-Naggar, AK, Chan, JKC, Grandis, JR, Takata, T, Slootweg, P. WHO Classification of Head and Neck Tumours. 4th ed. IARC Press;2017.
Google Scholar2. Kokubun, K, Yamamoto, K, Nakajima, K, et al. Frequency of odontogenic tumors: a single center study of 1089 cases in Japan and literature review. Head and Neck Pathol. Published online October 30, 2021. doi:10.1007/s12105-021-01390-w
Google Scholar | Crossref3. Soluk-Tekkesin, M, Cakarer, S, Aksakalli, N, Alatli, C, Olgac, V. New world health organization classification of odontogenic tumours: impact on the prevalence of odontogenic tumours and analysis of 1231 cases from Turkey. B J Oral Maxillofac Surg. 2020;58(8):1017-1022. doi:10.1016/j.bjoms.2020.06.033
Google Scholar | Crossref | Medline4. Sham, E, Leong, J, Maher, R, Schenberg, M, Leung, M, Mansour, AK. Mandibular ameloblastoma: clinical experience and literature review. ANZ J Surg. 2009;79(10):739-744. doi:10.1111/j.1445-2197.2009.05061.x
Google Scholar | Crossref | Medline5. Jhamb, T, Kramer, JM. Molecular concepts in the pathogenesis of ameloblastoma: implications for therapeutics. Exp Mol Pathol. 2014;97(3):345-353. doi:10.1016/j.yexmp.2014.09.001
Google Scholar | Crossref | Medline6. Kurppa, KJ, Catón, J, Morgan, PR, et al. High frequency of BRAF V600E mutations in ameloblastoma. J Pathol. 2014;232(5):492-498. doi:10.1002/path.4317
Google Scholar | Crossref | Medline | ISI7. Sweeney, RT, McClary, AC, Myers, BR, et al. Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nat Genet. 2014;46(7):722-725. doi:10.1038/ng.2986
Google Scholar | Crossref | Medline | ISI8. Guimarães, LM, Coura, BP, Gomez, RS, Gomes, CC. The molecular pathology of odontogenic tumors: expanding the spectrum of MAPK pathway driven tumors. Front Oral Health. 2021;2:740788. doi:10.3389/froh.2021.740788
Google Scholar | Crossref9. Puxeddu, E, Durante, C, Avenia, N, Filetti, S, Russo, D. Clinical implications of BRAF mutation in thyroid carcinoma. Trends Endocrinol Metab. 2008;19(4):138-145. doi:10.1016/j.tem.2007.12.003
Google Scholar | Crossref | Medline | ISI10. Dankort, D, Curley, DP, Cartlidge, RA, et al. Braf(V600E) cooperates with pten loss to induce metastatic melanoma. Nat Genet. 2009;41(5):544-552. doi:10.1038/ng.356
Google Scholar | Crossref | Medline | ISI11. Davies, H, Bignell, GR, Cox, C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954. doi:10.1038/nature00766
Google Scholar | Crossref | Medline | ISI12. Brunner, P, Bihl, M, Jundt, G, Baumhoer, D, Hoeller, S. BRAF P.V600E mutations are not unique to ameloblastoma and are shared by other odontogenic tumors with ameloblastic morphology. Oral Oncol. 2015;51(10):e77-e78. doi:10.1016/j.oraloncology.2015.07.010
Google Scholar | Crossref | Medline13. Brown, NA, Rolland, D, McHugh, JB, et al. Activating FGFR2–RAS–BRAF mutations in ameloblastoma. Clin Cancer Res. 2014;20(21):5517-5526. doi:10.1158/1078-0432.CCR-14-1069
Google Scholar | Crossref | Medline | ISI14. Diniz, MG, Gomes, CC, Guimarães, BVA, et al. Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours. Tumour Biol. 2015;36(7):5649-5653. doi:10.1007/s13277-015-3238-0
Google Scholar | Crossref | Medline15. Soltani, M, Tabatabaiefar, MA, Mohsenifar, Z, et al. Genetic study of the BRAF gene reveals new variants and high frequency of the V600E mutation among Iranian ameloblastoma patients. J Oral Pathol Med. 2018;47(1):86-90. doi:10.1111/jop.12610
Google Scholar | Crossref | Medline16. Derakhshan, S, Aminishakib, P, Karimi, A, et al. High frequency of BRAF V600E mutation in Iranian population ameloblastomas. Med Oral Patol Oral Cir Bucal. 2020;25(4):e502-e507. doi:10.4317/medoral.23519
Google Scholar | Crossref | Medline17. Oh, KY, Cho, SD, Yoon, HJ, Lee, JI, Ahn, SH, Hong, SD. High prevalence of BRAF V600E mutations in Korean patients with ameloblastoma: clinicopathological significance and correlation with epithelial-mesenchymal transition. J Oral Pathol Med. 2019;48(5):413-420. doi:10.1111/jop.12851
Google Scholar | Crossref | Medline18. Seki-Soda, M, Sano, T, Ito, K, Yokoo, S, Oyama, T. An immunohistochemical and genetic study of BRAFV600E mutation in Japanese patients with ameloblastoma. Pathol Int. 2020;70(4):224-230. doi:10.1111/pin.12899
Google Scholar | Crossref | Medline19. Gültekin, SE, Aziz, R, Heydt, C, et al. The landscape of genetic alterations in ameloblastomas relates to clinical features. Virchows Arch. 2018;472(5):807-814. doi:10.1007/s00428-018-2305-5
Google Scholar | Crossref | Medline20. Fregnani, ER, Perez, DE, Paes de Almeida, O, et al. BRAF-V600E expression correlates with ameloblastoma aggressiveness. Histopathology. 2017;70(3):473-484. doi:10.1111/his.13095
Google Scholar | Crossref | Medline21. do Canto, AM, da Silva Marcelino, BMR, Schussel, JL, et al. Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas. Clin Oral Invest. 2019;23(2):779-784. doi:10.1007/s00784-018-2494-y
Google Scholar | Crossref | Medline22. Pereira, NB, Pereira, KMA, Coura, BP, et al. BRAFV600E Mutation in the diagnosis of unicystic ameloblastoma. J Oral Pathol Med. 2016;45(10):780-785. doi:10.1111/jop.12443
Google Scholar | Crossref | Medline23. da Silva Marcelino, BMR, Parise, GK, do Canto, AM, et al. Comparison of immunohistochemistry and DNA sequencing for BRAF V600E mutation detection in mandibular ameloblastomas. Appl Immunohistochem Mol Morphol. 2021;29(5):390-393. doi:10.1097/PAI.0000000000000904
Google Scholar | Crossref | Medline24. Estrella, JS, Tetzlaff, MT, Bassett, RL, et al. Assessment of BRAF V600E status in colorectal carcinoma: tissue-specific discordances between immunohistochemistry and sequencing. Mol Cancer Ther. 2015;14(12):2887-2895. doi:10.1158/1535-7163.MCT-15-0615
Google Scholar | Crossref | Medline25. Cha, YH, Cho, ES, Kang, HE, et al. Frequent oncogenic BRAF V600E mutation in odontogenic keratocyst. Oral Oncol. 2017;74:62-67. doi:10.1016/j.oraloncology.2017.09.016
Google Scholar | Crossref | Medline26. Méhes, G, Irsai, G, Bedekovics, J, et al. Activating BRAF V600E mutation in aggressive pediatric langerhans cell histiocytosis: demonstration by allele-specific PCR/direct sequencing and immunohistochemistry. Am J Surg Pathol. 2014;38(12):1644-1648. doi:10.1097/PAS.0000000000000304
Google Scholar | Crossref | Medline27. Thiel, A, Heinonen, M, Kantonen, J, et al. BRAF Mutation in sporadic colorectal cancer and lynch syndrome. Virchows Arch. 2013;463(5):613-621. doi:10.1007/s00428-013-1470-9
Google Scholar | Crossref | Medline28. Long, GV, Wilmott, JS, Capper, D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol. 2013;37(1):61-65. doi:10.1097/PAS.0b013e31826485c0
Google Scholar | Crossref | Medline29. Vakiani, E, Yaeger, R, Brooke, S, Zhou, Y, Klimstra, DS, Shia, J. Immunohistochemical detection of the BRAF V600E mutant protein in colorectal neoplasms. Appl Immunohistochem Mol Morphol. 2015;23(6):438-443. doi:10.1097/PAI.0000000000000116
Google Scholar | Crossref | Medline30. Shirsat, PM, Bansal, S, Prasad, P, Desai, RS. Low frequency of BRAF V600E immunoexpression in mandibular ameloblastomas: an institutional study. J Oral Maxillofac Pathol. 2018;22(3):353-359. doi:10.4103/jomfp.JOMFP_174_17
Google Scholar | Crossref | Medline31. Owens, DM, Watt, FM. Contribution of stem cells and differentiated cells to epidermal tumours. Nat Rev Cancer. 2003;3(6):444-451. doi:10.1038/nrc1096
Google Scholar | Crossref | Medline32. Wicking, C, Smyth, I, Bale, A. The hedgehog signalling pathway in tumorigenesis and development. Oncogene. 1999;18(55):7844-7851. doi:10.1038/sj.onc.1203282
Google Scholar | Crossref | Medline33. Abe, M, Zong, L, Abe, T, et al. BRAF Inhibitor: a novel therapy for ameloblastoma in mandible. Chin J Cancer Res. 2018;30(6):677-678. doi:10.21147/j.issn.1000-9604.2018.06.12
Google Scholar | Crossref | Medline34. Broudic-Guibert, M, Blay, JY, Vazquez, L, et al. Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report. J Med Case Rep. 2019;13(1):245. doi:10.1186/s13256-019-2140-6
Google Scholar | Crossref | Medline35. Faden, DL, Algazi, A. Durable treatment of ameloblastoma with single agent BRAFi Re: clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma. J Natl Cancer Inst. 2017;109(1):djw190. doi:10.1093/jnci/djw190
Google Scholar | Crossref | Medline36. Kaye, FJ, Ivey, AM, Drane, WE, Mendenhall, WM, Allan, RW. Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma. J Natl Cancer Inst. 2015;107(1):378. doi:10.1093/jnci/dju378
Google Scholar | Crossref | Medline